Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial
Authors:
Open Access
- 18 October 2022
- journal article
- research article
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 16 (1) , 10-14
Abstract
Common inflammatory airway disorders, such as seasonal and perennial allergic rhinitis, acute sinusitis, and nasal polyposis, can have a significant impact on patient health and quality of life. Intranasal corticosteroids are recommended as part of treatment plans for each of these illnesses because they reduce inflammation and thus symptoms. In order to compare the efficacy and safety of a new nano formulation of mometasone furoate nano-nasal spray (MF-NNS) with a commercially available nasal spray called mometasone furoate nasal spray (MFNS) for the treatment of allergic rhinitis, 20 rhinitis patients were enrolled in this randomized controlled trial (10 to 50 years). Patients were given 50 mcg MF-NNS doses in the morning and evening. This regimen was administered as a nasal spray for a 3-week efficacy and safety phase. The primary endpoints changed from baseline in the subjects’ congestion as determined by the physicians’ assessment of allergic rhinitis. Analysis of variance was used to evaluate all efficacy end points. More clinical trials have shown that MF-NNS reduces both objective and subjective markers of inflammation in adults, adolescents, and children.Keywords
This publication has 13 references indexed in Scilit:
- Pathogenesis of rhinitisClinical & Experimental Allergy, 2016
- Optimal management of allergic rhinitisArchives of Disease in Childhood, 2015
- Impact of Sleep as a Specific Marker of Quality of Life in Allergic RhinitisCurrent Allergy and Asthma Reports, 2012
- Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitisAllergy and Asthma Proceedings, 2012
- Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitisCurrent Medical Research and Opinion, 2010
- A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary careHealth Technology Assessment, 2009
- Allergic rhinitis: past, present and the futureClinical Otolaryngology, 2003
- IgE‐Mediated Asthma and Rhinitis I: A Role of Allergen Exposure?Basic & Clinical Pharmacology & Toxicology, 2002
- Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosisJournal of Allergy and Clinical Immunology, 2001
- Mometasone Furoate Nasal Spray is Rapidly Effective in the Treatment of Seasonal Allergic Rhinitis in an Outdoor (Park), Acute Exposure SettingAllergy and Asthma Proceedings, 1999